Abstract
Objective Since its introduction 50 years ago, the contraceptive pill has continuously evolved to decrease the risk of venous thromboembolism (VTE) associated with its use. An increased risk of VTE still remains, however. Other concerns, such as effects on lipid and carbohydrate metabolism, have also been reported. In this study we compared two reference combined oral contraceptives (COCs) containing ethinylestradiol (EE)/levonorgestrel (LNG) and EE/drospirenone (DRSP) with COCs containing estradiol (E2) (estradiol valerate [E2V]/dienogest [DNG] and E2/nomegestrol acetate [NOMAC]). They were evaluated according to their influence on recognised haemostatic and metabolic markers.Methods A literature search of the MEDLINE/PubMed database was conducted for head-to-head studies. EE/LNG was chosen as the comparator pill.Results The haemostatic impact of E2 pills and EE/LNG has been extensively compared, in contrast to that of EE/DRSP and EE/LNG. Changes in haemostatic and metabolic marker levels between EE/LNG and E2V/DNG were generally not statistically significant. E2/NOMAC showed statistically significantly favourable results on haemostatic markers and had a neutral effect on carbohydrate and lipid metabolism when compared with EE/LNG.Conclusion E2/NOMAC exhibits less haemostatic and metabolic impact than EE/LNG and other COCs, suggesting that it may be a promising candidate to reduce residual VTE risk associated with COC use. Confirmation from a well-powered prospective clinical trial is, however, needed. Chinese Abstract 50,(VTE)EE/LNG/DRSP2(COCs)E2[E2V] /[DNG]/[NOMAC]MEDLINE/PubMed//////////
| Original language | English |
|---|---|
| Pages (from-to) | 329-343 |
| Number of pages | 15 |
| Journal | European Journal of Contraception and Reproductive Health Care |
| Volume | 20 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sep 3 2015 |
Fingerprint
Keywords
- Combined oral contraceptive
- Estradiol
- Ethinylestradiol
- Haemostatic markers
- Markers of lipid and carbohydrate metabolism
- Progestin
- Venous thromboembolism
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Pharmacology (medical)
- Reproductive Medicine
Cite this
Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills : A literature review. / Lete, Iñaki; Chabbert-Buffet, Nathalie; Jamin, Christian; Lello, Stefano; Lobo, Paloma; Nappi, Rossella E.; Pintiaux, Axelle.
In: European Journal of Contraception and Reproductive Health Care, Vol. 20, No. 5, 03.09.2015, p. 329-343.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills
T2 - A literature review
AU - Lete, Iñaki
AU - Chabbert-Buffet, Nathalie
AU - Jamin, Christian
AU - Lello, Stefano
AU - Lobo, Paloma
AU - Nappi, Rossella E.
AU - Pintiaux, Axelle
PY - 2015/9/3
Y1 - 2015/9/3
N2 - Objective Since its introduction 50 years ago, the contraceptive pill has continuously evolved to decrease the risk of venous thromboembolism (VTE) associated with its use. An increased risk of VTE still remains, however. Other concerns, such as effects on lipid and carbohydrate metabolism, have also been reported. In this study we compared two reference combined oral contraceptives (COCs) containing ethinylestradiol (EE)/levonorgestrel (LNG) and EE/drospirenone (DRSP) with COCs containing estradiol (E2) (estradiol valerate [E2V]/dienogest [DNG] and E2/nomegestrol acetate [NOMAC]). They were evaluated according to their influence on recognised haemostatic and metabolic markers.Methods A literature search of the MEDLINE/PubMed database was conducted for head-to-head studies. EE/LNG was chosen as the comparator pill.Results The haemostatic impact of E2 pills and EE/LNG has been extensively compared, in contrast to that of EE/DRSP and EE/LNG. Changes in haemostatic and metabolic marker levels between EE/LNG and E2V/DNG were generally not statistically significant. E2/NOMAC showed statistically significantly favourable results on haemostatic markers and had a neutral effect on carbohydrate and lipid metabolism when compared with EE/LNG.Conclusion E2/NOMAC exhibits less haemostatic and metabolic impact than EE/LNG and other COCs, suggesting that it may be a promising candidate to reduce residual VTE risk associated with COC use. Confirmation from a well-powered prospective clinical trial is, however, needed. Chinese Abstract 50,(VTE)EE/LNG/DRSP2(COCs)E2[E2V] /[DNG]/[NOMAC]MEDLINE/PubMed//////////
AB - Objective Since its introduction 50 years ago, the contraceptive pill has continuously evolved to decrease the risk of venous thromboembolism (VTE) associated with its use. An increased risk of VTE still remains, however. Other concerns, such as effects on lipid and carbohydrate metabolism, have also been reported. In this study we compared two reference combined oral contraceptives (COCs) containing ethinylestradiol (EE)/levonorgestrel (LNG) and EE/drospirenone (DRSP) with COCs containing estradiol (E2) (estradiol valerate [E2V]/dienogest [DNG] and E2/nomegestrol acetate [NOMAC]). They were evaluated according to their influence on recognised haemostatic and metabolic markers.Methods A literature search of the MEDLINE/PubMed database was conducted for head-to-head studies. EE/LNG was chosen as the comparator pill.Results The haemostatic impact of E2 pills and EE/LNG has been extensively compared, in contrast to that of EE/DRSP and EE/LNG. Changes in haemostatic and metabolic marker levels between EE/LNG and E2V/DNG were generally not statistically significant. E2/NOMAC showed statistically significantly favourable results on haemostatic markers and had a neutral effect on carbohydrate and lipid metabolism when compared with EE/LNG.Conclusion E2/NOMAC exhibits less haemostatic and metabolic impact than EE/LNG and other COCs, suggesting that it may be a promising candidate to reduce residual VTE risk associated with COC use. Confirmation from a well-powered prospective clinical trial is, however, needed. Chinese Abstract 50,(VTE)EE/LNG/DRSP2(COCs)E2[E2V] /[DNG]/[NOMAC]MEDLINE/PubMed//////////
KW - Combined oral contraceptive
KW - Estradiol
KW - Ethinylestradiol
KW - Haemostatic markers
KW - Markers of lipid and carbohydrate metabolism
KW - Progestin
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84942941149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942941149&partnerID=8YFLogxK
U2 - 10.3109/13625187.2015.1050091
DO - 10.3109/13625187.2015.1050091
M3 - Article
C2 - 26007631
AN - SCOPUS:84942941149
VL - 20
SP - 329
EP - 343
JO - European Journal of Contraception and Reproductive Health Care
JF - European Journal of Contraception and Reproductive Health Care
SN - 1362-5187
IS - 5
ER -